Pro 2014-001 (Announcement of Resolution of 14th Session of 8th Board of Directors of Jianfeng Group)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2014-001
浙江尖峰集团股份有限公司
八届十四次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
二〇一四年三月三十一日,浙江尖峰集团股份有限公司以传真、电子邮件及专人送达的方式发出了召开第八届董事会第十四次会议的通知。二〇一四年四月十一日,会议如期在浙江金华尖峰大厦会议室召开。会议由蒋晓萌董事长主持,独立董事邓明然因出差委托独立董事刘家健出席会议,其余八名董事亲自参加了会议;公司监事和高级管理人员列席了会议,符合《公司法》和公司《章程》的有关规定,所做决议合法有效。会议通过了如下决议:
一、通过了2013年度总经理业务报告
经审议,董事会一致通过了该报告,认为2013年公司经营班子的工作是卓有成效的,较好完成了各项经营任务,取得了良好的经营业绩;董事会批准了报告中提出的2014年各项工作安排。
表决结果:同意9票、反对0票、弃权0票。
二、通过了2013年度财务决算报告
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
三、通过了2013年度利润分配预案
经天健会计师事务所审计,2013年度公司合并报表归属于母公司股东的净利润为201,569,075.92元;母公司会计报表净利润40,440,909.88元。按母公司的本期净利润40,440,909.88元为基数,提取10%法定公积金4,044,090.99元,加年初未分配利润291,235,211.25元,减去2012年度现金分红51,612,574.2元,本年度可供分配利润为276,019,455.94 元。
公司2013年度拟进行现金分配,以2013年末股本344,083,828股为基数,每10股派发现金红利1.8元(含税),向股权登记日登记在册的全体股东派发现金股利总额为61,935,089.04 元(含税)。2013年度不进行公积金转增股本。
表决结果:同意9票、反对0票、弃权0票。
该预案将提交股东大会审议。
四、通过了聘请2014年度审计机构的议案
董事会审议并通过了该议案,同意聘请天健会计师事务所为公司2014年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
该议案将提交股东大会审议。
五、通过了关于计提资产减值准备和核销资产的议案
董事会审议并通过了该议案,同意计提以下资产减值准备和核销以下已全额计提减值准备的资产:
(一)计提资产减值准备的情况:
1、子公司浙江尖峰药业有限公司秋滨制药厂因实施GMP改造,计提设备等固定资产减值准备218.65万元。
2、子公司浙江尖峰通信电缆有限公司部分车间因转型拆除,计提固定资产减值准备51.84万元和存货跌价准备21.68万元。
3、子公司浙江尖峰国际贸易有限公司因开展代理进口电解铜业务,产生应收帐款纠纷,并已向法院提起诉讼并申请了资产保全。经测算,对该笔应收帐款计提坏帐准备564.82万元。
4、经测试,子公司浙江尖峰通信电缆有限公司和浙江尖峰国际贸易公司的商誉发生了减值,共需计提商誉减值准备73.10万元,其中:尖峰电缆47.15万元,尖峰国贸25.95万元。
以上计提资产减值准备金额合计930.09万元。
(二)资产核销的情况:
公司应收参股子公司博信电池(上海)有限公司的暂借款600万元(2008年以前发生),因该公司已停止经营,且该借款期限也已超过五年,确定无法收回,予以核销。该借款已于以前年度全额计提坏账准备,本次核销不影响当期损益。
表决结果:同意9票、反对0票、弃权0票。
六、通过了2013年年度报告及其摘要
表决结果:同意9票、反对0票、弃权0票。
该报告需提交股东大会审议。
2013年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
七、通过了关于为控股子公司提供担保的议案
董事会一致通过了该议案,同意为控股子公司提供以下担保事宜。
1、对控股子公司向金融机构借款提供担保,设定如下额度:
|
被担保单位 |
设定担保额度(万元) |
|
大冶尖峰水泥有限公司 |
10000 |
|
浙江尖峰药业有限公司 |
20000 |
|
金华市医药公司 |
10000 |
|
浙江尖峰国际贸易有限公司 |
5000 |
|
云南尖峰水泥有限公司 |
5000 |
|
合计 |
50000 |
2、同意为浙江尖峰国际贸易有限公司提供担保函,为浙江尖峰国际贸易有限公司的客户在该公司存放的货物提供相应的担保。
在以上额度内的担保授权董事长分次执行。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《对控股子公司提供担保的公告》(临2014-003)。
八、通过了与浙江凯恩特种材料股份有限公司互相担保的议案
董事会审议并通过了该议案,同意与浙江凯恩特种材料股份有限公司进行额度为5000万元、期限为一年的等额互保。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《与浙江凯恩特种材料股份有限公司互相担保的公告》(临2014-004)。
九、通过了公司《章程》修订议案
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《关于修订章程的公告》(临2014-007)。
十、通过了日常关联交易议案
董事会审议并通过了该议案。关联董事蒋晓萌先生、杜自弘先生回避了该项议案的表决。
表决结果:同意7票、反对0票、弃权0票。
详见《日常关联交易公告》(临2014-005)。
十一、通过了聘任证券事务代表的议案
董事会审议并通过了该议案,决定聘任周恒斌先生为本公司的证券事务代表。周恒斌先生的简历附后。
表决结果:同意9票、反对0票、弃权0票。
十二、通过了2013年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2013年度内部控制评价报告详见上海证券交易所网站(www.sse.com.cn)。
十三、通过了2013年独立董事述职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
该报告需提交股东大会审议。
2013年独立董事述职报告详见上海证券交易所网站(www.sse.com.cn)。
十四、通过了2013年度审计委员会履职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
2013年度审计委员会履职报告详见上海证券交易所网站(www.sse.com.cn)。
十五、通过了关于召开2013年度股东大会的议案
董事会决定于2014年6月6日在浙江省金华市婺江东路88号尖峰大厦召开2013年度股东大会。
表决结果:同意9票、反对0票、弃权0票
详见《关于召开2013年度股东大会的通知》(临2014-006)。
十六、通过了关于对子公司增加注册资本的议案
董事会审议并通过了该议案。同意公司用自有资金1500万元对子公司浙江尖峰健康科技有限公司进行增资,增资完成后该子公司注册资本增加到3000万元,本公司持有其100%股权。
表决结果:同意9票、反对0票、弃权0票
十七、通过了关于注销浙江金华中能物产有限公司的议案
表决结果:同意9票、反对0票、弃权0票。
详见《关于注销子公司的公告》(临2014-008)。
十八、通过了2013年度董事会工作报告
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一四年四月十五日
简历:
周恒斌,男,1986年10月出生,大学本科。2010年1月加入本公司,曾在浙江尖峰药业有限公司工作,2013年4月至今在本公司董事会办公室工作。已参加上海证券交易所举办的相关培训,并取得了上海证券交易所颁发的董事会秘书资格证书。
电话:0579-82324699
传真:0579-82324699
邮箱:jf@jianfeng.com.cn
地址:浙江省金华市婺江东路88号
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11